Physician profile
James Chapman
NPI 1124030002
$3,284.91
in general payments reported to CMS, 2019-2025
21 companies · $712 in 2025
The $712 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $97.77 · 2021: $250 · 2022: $341 · 2023: $602 · 2024: $752 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $728.59 | 2021-2025 | Verquvo, Belsomra |
| Pfizer INC. | $466.68 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $419.05 | 2021-2025 | |
| Abiomed | $414.24 | 2024-2025 | Impella |
| Amgen INC. | $235.49 | 2019-2021 | |
| Boston Scientific Corporation | $144.99 | 2022-2025 | General - Therapies, Watchman Flx |
| Abbott Laboratories | $129.55 | 2019-2023 | Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.50 | 2021-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $125.16 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $92.47 | 2019-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $85.63 | 2025 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $70.61 | 2019-2025 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.60 | 2020-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $42.54 | 2021-2023 | Andexxa |
| Chiesi USA, INC. | $27.91 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.89 | 2023 | Corevalve Evolut R |
| Philips North America LLC | $19.32 | 2024 | (Ck4) Mcot |
| Lundbeck LLC | $18.55 | 2019 | |
| Genentech USA, INC. | $17.97 | 2021 | |
| Edwards Lifesciences Corporation | $15.27 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.